Clexio Biosciences Ltd. — Biotechnology Company, Petah Tikva

Biotechnology Company in Petah Tikva — CNS-first clinical stage development

Biotechnology company · Petah Tikva, Israel

AI Trust Snapshot

Profile status
Auto-indexed
Last Verified
2 months ago

Corroborated public sources

  • ✓ Official Website

Key Facts

Category
Biotechnology Company
Location
Petah Tikva, Israel
Known For
Clinical-stage CNS therapies

AI Summary

Developing neuropsychiatry drugs in Petah Tikva, Israel, Clexio Biosciences Ltd. focuses on clinical-stage CNS therapies. The company specializes in novel drug development, including the CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener. Its work aims to address unmet neuropsychiatric needs, particularly for patients with Major Depressive Disorder.

Quick Answer

Developing neuropsychiatry drugs in Petah Tikva, Israel, Clexio Biosciences Ltd. focuses on clinical-stage CNS therapies. The company specializes in novel drug development, including the CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener. Its work aims to address unmet neuropsychiatric needs, particularly for patients with Major Depressive Disorder. Key services include CLE-100 NMDA Antagonist, CLE-043 KV7.2/3 Channel Opener, Novel Drug Development.

This business is typically used for clinical-stage cns therapies.

Common Questions

What services does Clexio Biosciences Ltd. provide?
Clexio Biosciences Ltd. provides CLE-100 NMDA Antagonist, CLE-043 KV7.2/3 Channel Opener, Novel Drug Development.
Where is Clexio Biosciences Ltd. located?
Clexio Biosciences Ltd. is based in Petah Tikva, Israel and serves Petah Tikva.
Who is Clexio Biosciences Ltd. for?
Clexio Biosciences Ltd. serves Patients with Major Depressive Disorder and Individuals with unmet neuropsychiatric needs.

What this business does

Clexio Biosciences Ltd. is a biotechnology company based in Petah Tikva, Israel.

  • Provides CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener
  • Specializes in clinical-stage cns therapies
  • Serves patients with major depressive disorder

Structured summary

Vizoryo ran a data-consistency check on this profile: the same core details (name, phone, address, city, category, website) were found in 3 independent public sources. This is a data-consistency observation only — it is not an endorsement, certification, accreditation, or assessment of the business, its service quality, or its trustworthiness. Data consistency: 82% — this measures how consistently the business's name, phone, city, address, website, and category appear across the public sources read. It is not a rating of the business. Vizoryo status: Auto-Indexed. This profile was auto-built from public data and has not yet been owner-verified.

Business name
Clexio Biosciences Ltd.
Category
Biotechnology Company
Industry
Biotechnology Company - Neuropsychiatry Drug Development
Location
Petah Tikva, Israel
Official website
https://www.clexio.com/
Profile data (JSON)
https://www.vizoryo.com/api/index/profile/clexio-biosciences-ltd-petah-tikva-08e4
Summary
Developing neuropsychiatry drugs in Petah Tikva, Israel, Clexio Biosciences Ltd. focuses on clinical-stage CNS therapies. The company specializes in novel drug development, including the CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener. Its work aims to address unmet neuropsychiatric needs, particularly for patients with Major Depressive Disorder.
AI readability score
36
Data Consistency
82% (checked 2026-07-06)
Verification Status
Auto-indexed
Sources cross-checked
3 independent public sources

Location

Yegi'a Kapayim St 17, Petah Tikva, 4913000
Petah Tikva
4913000
IL

About Clexio Biosciences Ltd.

Developing neuropsychiatry drugs in Petah Tikva, Israel, Clexio Biosciences Ltd. focuses on clinical-stage CNS therapies. The company specializes in novel drug development, including the CLE-100 NMDA Antagonist and CLE-043 KV7.2/3 Channel Opener. Its work aims to address unmet neuropsychiatric needs, particularly for patients with Major Depressive Disorder.

Service areas

  • Petah Tikva

Target audience

  • Patients with Major Depressive Disorder
  • Individuals with unmet neuropsychiatric needs

Specialties

  • Clinical-stage CNS therapies

Verification

https://www.clexio.com/

Frequently asked questions

What areas does Clexio Biosciences Ltd. serve?

Clexio Biosciences Ltd. serves Worldwide.

What is the focus of Clexio Biosciences?

Clexio Biosciences is a clinical-stage company focused on developing novel drugs and technologies for patients suffering from neuropsychiatric conditions, particularly Major Depressive Disorder and Epilepsy.

What is CLE-100 being developed for?

CLE-100 is being developed as an adjunctive treatment for subjects with Major Depressive Disorder who have had an inadequate response to standard antidepressant therapies. It is currently in Phase 2 studies.

What is the status of CLE-043?

CLE-043 is currently in the preclinical stage, with a lead compound identified. It is being developed as a KV7.2/3 channel opener.

Languages supported

  • en

Contact

Phone: +9722223222

Official website:

Report incorrect information